Navigation Links
Grant initiates new stem cell research for patients suffering with corneal blindness
Date:6/21/2013

LOS ANGELES (June 21, 2013) Corneal blindness affects roughly 8 million people worldwide, and traditional treatments and surgical interventions have seen little long-term success. With a new vision for stem cell corneal transplantation, and a $1.25 million grant from the National Eye Institute, Cedars-Sinai co-investigators Alexander V. Ljubimov, PhD, FARVO, and Clive Svendsen, PhD, hope to treat previously untreatable patients suffering with corneal blindness.

"Our proposed and first-of-a-kind research deals with collecting human eye cells, reprograming them back in time to a stem cell state and then using them to create a corneal cell source for transplantation. If successful, this could result in future human clinical trials that may lead to improved vision and overall quality of life," said Ljubimov, principal investigator of the grant and director of the Eye Program at the Cedars-Sinai Regenerative Medicine Institute. "We are first experimenting with allogeneic cells from eye donors, but hope to use person's own cells in the near future."

A common cause of corneal blindness is limbal epithelial stem cell deficiency, which means that a patient's history of genetics or eye injuries results in corneal scarring, blood vessel growth, and outgrowth of conjunctiva, all of which lead to vision loss.

This stem cell therapy approach uses induced pluripotent stem cells (iPSC), which are adult cells that are genetically reprogrammed to function as embryonic stem cells. Typically, iPSC technology has used stem cells from other places in the patient's body, such as the skin, or from donor cells. However, advances in stem cell technology could make it possible for doctors to harvest stem cells from a patient's own cornea or sclera (the white of the eye) and then transplant the reprogrammed cells back into the cornea of the patient.

"If successful, this new approach may pave the way for human trials in patients affected by limbal epithelial stem cell deficiency," said Svendsen, director of the Cedars-Sinai Regenerative Medicine Institute. "The engineering of a patient's own adult stem cells to embryonic stem-like cells for the use in corneal transplantation may provide a noteworthy treatment alternative to patients affected worldwide."

Svendsen and Ljubimov lead a highly respected research team that includes Mehrnoosh Saghizadeh, PhD, co-investigator of the grant and assistant professor of surgery; Yaron Rabinowitz, MD, director of Ophthalmology Research and co-investigator of the grant; and Dhruv Sareen, PhD, director of the Regenerative Medicine Institute's iPSC core facility.

The research project grant is the first NIH R01 grant awarded to the newly established Cedars-Sinai Regenerative Medicine Institute and was given under the application "Stem Cell Approaches to Developing New Therapies for Ocular Diseases."

This grant aims to restore function in diseased eye tissues through the revitalization of existing cells or the transplantation of new cells. The National Eye Institute, part of the National Institutes of Health, leads the federal government's research on the visual system and eye diseases and supports basic and clinical science programs that result in the development of sight-saving treatments.


'/>"/>

Contact: Cara Lasala
cara.lasala@cshs.org
310-423-7798
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Washingtons Life Sciences Discovery Fund awards commercialization grants
3. University of Cincinnati researchers win $3.7M grant from US Department of Defense
4. $9 million grant awarded to UH to study, treat learning disabilities
5. Louisiana Tech University professor earns NSF Early Career Development grant
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
8. 2 Grand Challenges Explorations grants for global health
9. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
10. LA BioMed receives Grand Challenges Explorations grant
11. UC San Diego Superfund Research Program receives $15 million grant renewal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: